公开(公告)号：US20180362502A1

公开(公告)日：2018-12-20

申请号：US15988783

申请日：2018-05-24

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Brett Granger ,  Guoqiang Wang ,  Ruichao Shen ,  Jun Ma ,  Xuechao Xing ,  Jing He ,  Yong He ,  Jiang Long ,  Bin Wang ,  Yat Sun Or

IPC: C07D401/14 ,  C07D417/14 ,  C07D513/04 ,  C07D491/08 ,  C07D487/08

CPC classification number: C07D401/14 ,  C07D417/14 ,  C07D487/08 ,  C07D491/08 ,  C07D513/04

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).

公开(公告)号：US10149835B2

公开(公告)日：2018-12-11

申请号：US15597431

申请日：2017-05-17

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Yat Sun Or ,  Xuechao Xing ,  Ruichao Shen ,  Bin Wang ,  Brett Granger ,  Jun Ma ,  Jing He ,  Jiang Long ,  Yong He ,  Guoqiang Wang

IPC: A61K31/42 ,  C07D225/04 ,  C07D213/127 ,  C07D261/08 ,  C07C317/38

Abstract: The present invention provides compounds of Formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated by FXR. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR and methods for their preparation and use.

公开(公告)号：US10080743B2

公开(公告)日：2018-09-25

申请号：US15497359

申请日：2017-04-26

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Yat Sun Or ,  Bin Wang ,  Xuechao Xing ,  Ruichao Shen ,  Brett Granger ,  Jun Ma ,  Jing He ,  Yong He ,  Jiang Long ,  Guoqiang Wang

IPC: C07D261/08 ,  C07D413/12 ,  A61K31/42 ,  A61K31/422

CPC classification number: A61K31/42 ,  A61K31/422 ,  C07D261/08 ,  C07D413/12

Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated as FXR modulators. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.

公开(公告)号：US09603895B2

公开(公告)日：2017-03-28

申请号：US14843119

申请日：2015-09-02

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Yat Sun Or ,  Guoqiang Wang ,  Jiang Long ,  Xuri Gao

IPC: A61K38/00 ,  C07K5/00 ,  C07K7/00 ,  C07K16/00 ,  C07K17/00 ,  A61K38/13 ,  A61K31/7088 ,  A61K38/21 ,  A61K45/00 ,  C07K7/52 ,  A61K45/06 ,  C07K7/64

CPC classification number: A61K38/13 ,  A61K31/7088 ,  A61K38/21 ,  A61K45/00 ,  A61K45/06 ,  C07K7/52 ,  C07K7/645 ,  Y02A50/463

Abstract: The present invention relates to cyclosporin analogues having antiviral activity against HCV and useful in the treatment of HCV infections. More particularly, the invention relates to novel cyclosporin analogue compounds, compositions containing such compounds and methods for using the same, as well as processes for making such compounds.

公开(公告)号：US20160176917A1

公开(公告)日：2016-06-23

申请号：US14976294

申请日：2015-12-21

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Guoqiang Wang ,  Yat Sun Or ,  Ruichao Shen ,  Jiang Long ,  Peng Dai ,  Xuechao Xing ,  Jing He

IPC: C07J43/00 ,  C07J41/00

CPC classification number: C07J43/003 ,  C07J41/0055 ,  C07J41/0088

Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.

Abstract translation: 本发明提供式I化合物，包含这些化合物的药物组合物以及使用这些化合物预防或治疗FXR介导的或TGR5介导的疾病或病症的方法。

公开(公告)号：US20160051625A1

公开(公告)日：2016-02-25

申请号：US14843119

申请日：2015-09-02

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Yat Sun Or ,  Guoqiang Wang ,  Jiang Long ,  Xuri Gao

IPC: A61K38/13 ,  A61K45/06 ,  C07K7/64

CPC classification number: A61K38/13 ,  A61K31/7088 ,  A61K38/21 ,  A61K45/00 ,  A61K45/06 ,  C07K7/52 ,  C07K7/645 ,  Y02A50/463

Abstract: The present invention relates to cyclosporin analogues having antiviral activity against HCV and useful in the treatment of HCV infections. More particularly, the invention relates to novel cyclosporin analogue compounds, compositions containing such compounds and methods for using the same, as well as processes for making such compounds.

公开(公告)号：US20140154208A1

公开(公告)日：2014-06-05

申请号：US14092171

申请日：2013-11-27

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Yat Sun Or ,  In Jong Kim ,  Jiang Long ,  Lijuan Jiang ,  Sheng Sean Liu ,  Guoqiang Wang

IPC: C07K7/64 ,  A61K45/06 ,  A61K31/7056 ,  A61K38/13 ,  A61K31/713

CPC classification number: C07K7/645 ,  A61K31/7056 ,  A61K31/713 ,  A61K38/21 ,  A61K45/06 ,  C07K7/64 ,  Y02A50/463 ,  A61K2300/00 ,  A61K38/13

Abstract: The present invention relates to novel cyclosporine analogues having antiviral activity against HCV and useful in the treatment of HCV infections. More particularly, the invention relates to novel cyclosporine analogue compounds, compositions containing such compounds and methods for using the same, as well as processes for making such compounds.

Abstract translation: 本发明涉及对HCV具有抗病毒活性的新型环孢菌素类似物，可用于治疗HCV感染。 更具体地，本发明涉及新的环孢菌素类似物化合物，含有这些化合物的组合物及其使用方法，以及制备这些化合物的方法。

公开(公告)号：US20240228464A9

公开(公告)日：2024-07-11

申请号：US18383949

申请日：2023-10-26

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Guoqiang Wang ,  Ruichao Shen ,  Brett Granger ,  Jing He ,  Xuechao Xing ,  Yong He ,  Jiang Long ,  Jun Ma ,  Bin Wang ,  Yat Sun Or

IPC: C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14

CPC classification number: C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof:




which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which is associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

公开(公告)号：US20240207224A1

公开(公告)日：2024-06-27

申请号：US18509403

申请日：2023-11-15

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Jiajun Zhang ,  Xuri Gao ,  Hui Cao ,  Yuk Ming Siu ,  Bin Wang ,  Jiang Long ,  Wei Li ,  Matthew C. Rhodes ,  Xuechao Xing ,  Scott Mitchell ,  Yat Sun Or

IPC: A61K31/395 ,  A61K31/4192 ,  A61K31/4995 ,  A61P31/14 ,  C07D225/04 ,  C07D245/04 ,  C07D255/04 ,  C07D273/02 ,  C07D281/00 ,  C07D285/00 ,  C07D487/08

CPC classification number: A61K31/395 ,  A61K31/4192 ,  A61K31/4995 ,  A61P31/14 ,  C07D225/04 ,  C07D245/04 ,  C07D255/04 ,  C07D273/02 ,  C07D281/00 ,  C07D285/00 ,  C07D487/08

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof:




which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

公开(公告)号：US11008304B2

公开(公告)日：2021-05-18

申请号：US16400529

申请日：2019-05-01

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Guoqiang Wang ,  Ruichao Shen ,  Brett Granger ,  Jing He ,  Xuechao Xing ,  Yong He ,  Jiang Long ,  Jun Ma ,  Bin Wang ,  Yat Sun Or

IPC: C07D401/14 ,  C07D413/14 ,  C07D405/14 ,  C07D409/14 ,  C07D417/14

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which is associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).